Comparison of the Association Between High-Sensitivity Troponin I and Adverse Cardiovascular Outcomes in Patients With Versus Without Chronic Kidney Disease

Pratik B. Sandesara, Wesley T. O'Neal, Ayman Samman Tahhan, Salim S. Hayek, Suegene K. Lee, Jay Khambhati, Matthew L. Topel, Muhammad Hammadah, Ayman Alkhoder, Yi An Ko, Mohamad Mazen Gafeer, Agim Beshiri, Gillian Murtagh, Jonathan H. Kim, Peter Wilson, Leslee Shaw, Stephen E. Epstein, Laurence S. Sperling, Arshed A. Quyyumi

Resultado de la investigación: Articlerevisión exhaustiva

8 Citas (Scopus)

Resumen

It is unknown whether the association of high-sensitivity troponin I (hs-TnI) with adverse cardiovascular outcomes varies by the presence of chronic kidney disease (CKD). We examined the association of hs-TnI with adverse cardiovascular outcomes in those with and without CKD in 4,107 (mean age, 64 years; 63% men; 20% black) patients from the Emory Cardiovascular Biobank who underwent coronary angiography. CKD (n = 1,073) was defined as estimated glomerular filtration rate <60 ml/min/1.73 m2 or urine albumin/creatinine ratio >30 mg/g at baseline. Cox regression was used to compute hazard ratios (HR) for the association between hs-TnI levels (per doubling of hs-TnI: log2[hs-TnI] + 1) and death, cardiovascular death, and major adverse cardiac events (MACE), separately. Hs-TnI was a stronger predictor of death (CKD: HR 1.23, 95% confidence interval [CI] 1.15 to 1.31; no CKD: HR 1.11, 95% CI 1.05 to 1.17, p-interaction = 0.023), cardiovascular death (CKD: HR 1.24, 95% CI 1.14 to 1.34; no CKD: HR 1.15, 95% CI 1.07 to 1.22, p-interaction = 0.12), and MACE (CKD: HR 1.18, 95% CI 1.11 to 1.25; no CKD: HR 1.11, 95% CI 1.06 to 1.16, p-interaction = 0.095) in CKD compared with non-CKD. The association between hs-TnI and death in patients with CKD was stronger for patients without obstructive coronary artery disease (no obstructive coronary artery disease: HR 1.60, 95% CI 1.27 to 2.01; obstructive coronary artery disease: HR 1.19, 95% CI 1.11 to 1.27, p-interaction = 0.041). In conclusion, hs-TnI is a stronger predictor of adverse cardiovascular events in patients who have CKD than those without, even in the absence of obstructive coronary artery disease. Hs-TnI may identify CKD patients who are high risk for adverse cardiovascular outcomes in whom aggressive risk factor modification strategies are warranted.

Idioma originalEnglish (US)
Páginas (desde-hasta)1461-1466
Número de páginas6
PublicaciónAmerican Journal of Cardiology
Volumen121
N.º12
DOI
EstadoPublished - jun. 15 2018
Publicado de forma externa

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Huella

Profundice en los temas de investigación de 'Comparison of the Association Between High-Sensitivity Troponin I and Adverse Cardiovascular Outcomes in Patients With Versus Without Chronic Kidney Disease'. En conjunto forman una huella única.

Citar esto